tri agonist glp 1 LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor for glycemic control and weight loss: From discovery to clinical proof of concept: Cell Metabolism Retatrutide is a “triple agonist”

On 19 March 2026, the FDA approved a higher-dose formulation of semaglutide, Wegovy HD, at 7.2 mg for once-weekly subcutaneous administration

2016b;375:1834

Labs are not routinely required unless clinically necessary

Cahill, K

That's a reason to keep on top of your nutrition and strength-training while on these drugs, he writes, "especially for older people like me, who are [already] susceptible to muscle loss." There are people who should steer clear of GLP-1 drugs, Kessler notes, including those with a personal or familial history of certain thyroid and endocrine cancers, those with chronic kidney disease, pancreatitis, inflammatory bowel diseases, uncontrolled diarrhea or constipation or gastroparesis, or if you are pregnant